Evidence map›Paper›PMID 38605961›Full record

ArticleFrontiers in immunology2024

Co-formulation of the rF1V plague vaccine with depot-formulated cytokines enhances immunogenicity and efficacy to elicit protective responses against aerosol challenge in mice.

Darrell R Galloway, Jiahui Li, Nguyen X Nguyen, Frank W Falkenberg, Lisa Henning, Robert Krile, Ying-Liang Chou, James N Herron, J Scott Hale, E Diane Williamson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Darrell R GallowayDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, United States.
Jiahui LiDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, United States.
Nguyen X NguyenDepartment of Pathology, Division of Microbiology and Immunology, University of Utah, Salt Lake City, UT, United States.
Frank W FalkenbergCIRES, GmbH, Bochum, Germany.
Lisa HenningBattelle Biomedical Research Center, Columbus, OH, United States.
Robert KrileBattelle Biomedical Research Center, Columbus, OH, United States.
Ying-Liang ChouBattelle Biomedical Research Center, Columbus, OH, United States.
James N HerronDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, United States.
J Scott HaleDepartment of Pathology, Division of Microbiology and Immunology, University of Utah, Salt Lake City, UT, United States.
E Diane WilliamsonChemical Biological Radiological Division, Defense Science and Technology Laboratory (DSTL), Porton Down, Salisbury, United Kingdom.

Funding

NIAID NIH HHS HHSN272201200003I
6 · The paper itself

Abstract

This study evaluated a depot-formulated cytokine-based adjuvant to improve the efficacy of the recombinant F1V (rF1V) plague vaccine and examined the protective response following aerosol challenge in a murine model. The results of this study showed that co-formulation of the Alhydrogel-adsorbed rF1V plague fusion vaccine with the depot-formulated cytokines recombinant human interleukin 2 (rhuIL-2) and/or recombinant murine granulocyte macrophage colony-stimulating factor (rmGM-CSF) significantly enhances immunogenicity and significant protection at lower antigen doses against a lethal aerosol challenge. These results provide additional support for the co-application of the depot-formulated IL-2 and/or GM-CSF cytokines to enhance vaccine efficacy.

Indexed as

Plague VaccineYersinia pestisAerosolsAnimalsAntigens, BacterialCytokinesHumansMiceVaccines, SyntheticAerosolsAntigens, BacterialCytokinesPlague VaccineVaccines, Syntheticco-immunizationcytokine depot adjuvantimmune enhancementplague vaccineprotective antibody titersubunit vaccinevaccinationYersinia pestis

Identifiers

PMID38605961
PMCPMC11007139

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.